Kidney Cancer Clinical Trial

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

Summary

Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation techniques (AT), watchful waiting (WW), active surveillance (AS)) could be feasible with acceptable oncologic outcomes in particular settings of patients with localized renal tumors. In this complex clinical scenario, the role surgeon-related and environmental factors (such as surgical experience, hospital resources, countries' social background and performance of health system) are important to address the best personalized approach in patients with renal tumors.

In the light of current evidence, many unsolved questions still remain and many unmet needs must be addressed. In particular, 1) the risk-benefit trade-offs between PN and RN for anatomically complex renal localized tumors; 2) the definition of evidence-based strategies to tailor the management strategy (AT vs WW vs AS vs surgery) in different subset of patients with particular clinical conditions (i.e. old, frail, comorbid patients); and 3) the definition of evidence-based recommendations to adapt surgical approach (open vs laparoscopic vs robotic) and resection techniques to different patient-, tumor-, and surgeon-specific characteristics.

To meet the challenges, to overcome the limitations of current kidney cancer literature (such as the retrospective study design, potential risk of biases, and heterogeneous follow-up of most series), and to provide high-quality evidence for future development of effective clinical practice Guidelines, we designed the international REgistry of COnservative or Radical treatment of localized kiDney tumors (i-RECORD) Project.

The expected impact of the i-RECORD project is to provide robust evidence on the leading clinical and environmental factors driving selection of the management strategy in patients with kidney cancer, and the differential impact of different management strategies (including AS, WW, AT, PN and RN) on functional, perioperative and oncological outcomes, as well as quality of life assessment, at a mid-long term follow-up (5-10 years).

View Full Description

Full Description

Study design

The overall objective of the i-RECORD project is to build a multicentre multi-arm multi-stage prospective observational registry collecting data on the management of kidney cancer in consecutive patients treated at 50 tertiary referral Centers worldwide over a 2 years-period and with 5 years of follow-up

. On this registry, six prospective trials with specific objectives have been built.

The i-RECORd project is designed as an observational prospective longitudinal trial involving 50 international, very-high-volume tertiary referral Centers with extensive experience in management of kidney cancer. Centers will be included in the project only if they will be able to certify at least to: 1) perform 150 partial and radical nephrectomy/year, or 2) to perform 80 ATs/year, or 3) to include 50 patients in WW/AS protocols/year.

The enrollment and follow-up periods will be 2 and 5 years, respectively. The estimate of patients' enrollment over the study period is 10'000 inclusions.

The 50 Centers finally enrolled in the i-RECORD project will be given the access to a web-based platform for data collection for 24 months from the starting date of the project.

A web-based e-form platform will be used for data collection.

Data collection

This observational study aims to obtain controlled, qualitative and quantitative, data of the enrolled patients through a web-based e-form platform. For all patients it will be asked to complete a data collection form specifically designed for this study, consisting of some subfolders:

Anthropometric, pre-operative and comorbidity data (patient characteristics).
Imaging data e and pre-operative tumor features (tumor characteristics).
Intra-operative and post-operative data (treatment characteristics).
Histopathological analysis (tumor histopathological characteristics).
Patients follow-up variables (at 6, 12, 24 and 60 months from the treatment) (follow-up characteristics).

Decision Analysis Modeling

Beyond traditional descriptive and inferential statistical analyses, the i-RECORd project will provide a comprehensive overview of the current selection criteria for each type of management option by applying innovative statistical methods (Decision Analysis Modeling through discrete choice models) to determine the differential impact of all potential relevant variables on the choice of treatment. To do so, we will consider specific clinical scenarios (clinical clusters) made of the integration of patient characteristics (comorbidity score, performance status, age, gender, etc.), patient-reported outcomes measures (PROMs), tumors anatomical features (degree of complexity, clinical diameter, side, location within the kidney, involvement of renal sinus or collecting system, etc.), surgeon-related factors (surgical experience and background), hospital economic availabilities (i.e. open, laparoscopic, robotic surgery) and other country-specific socio-economical features in order to determine the impact of such variables on the final choice of treatment.

By applying the discrete choice model to the analysis of the prospective dataset, the i-RECORd project will overcome the current state of the art in the treatment of localized renal tumors as it will show how the choice of treatment is performed by the decision-maker (at a surgeon- and hospital-level) in each specific clinical cluster of patients, why that choice was performed according to a careful analysis of the personalized patient setting and whether that choice will influence the postoperative outcomes.

Adapted MAMS Registry

The i-RECORD will be designed adapting the innovative concept of multi-arm, multi-stage (MAMS) platform randomized trials (used, for instance, for the design of the Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) Trial) to create a dynamic, observational registry evaluating simultaneously different management options in different patient- and/or tumor-related scenarios.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Radiological diagnosis of renal tumor susceptible to active treatment or AS/WW.
Age ≥18 years
Informed consent signed

Exclusion Criteria:

Patient refuse to participate in clinical research.
Urothelial renal carcinoma.

Study is for people with:

Kidney Cancer

Estimated Enrollment:

10000

Study ID:

NCT05363657

Recruitment Status:

Recruiting

Sponsor:

Azienda Ospedaliero-Universitaria Careggi

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 37 Locations for this study

See Locations Near You

Institute of Urology, University of Southern California.
Los Angeles California, 90007, United States More Info
Giovanni E Cacciamani
Contact
[email protected]
University of California San Diego, Moores Cancer Center
San Diego California, 92037, United States More Info
Ithaar Derweesh
Contact
[email protected]
Stanford University
Stanford California, 94304, United States More Info
Benjamin I Chung
Contact
[email protected]
Loyola University Medical Center, Edward Hines VA Hospital
Chicago Illinois, 60141, United States More Info
Gopal Gupta
Contact
[email protected]
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States More Info
Philip Pierorazio
Contact
[email protected]
VCU Health System
Richmond Virginia, 23298, United States More Info
Riccardo Autorino
Contact
[email protected]
Swedish Hospital
Seattle Washington, 98122, United States More Info
James Porter
Contact
[email protected]
Medical University of Vienna, Vienna General Hospital
Vienna , 1090, Austria More Info
Shahkrokh F Shariat
Contact
[email protected]
University of Bruxelles
Bruxelles , 1050, Belgium More Info
Simone Albisinni
Contact
[email protected]
University Hospitals Leuven
Leuven , 3000, Belgium More Info
Maarten Albersen
Contact
[email protected]
Onze Lieve Vrouw Hospital
Leuven , 8500, Belgium More Info
Geert De Naeyer
Contact
[email protected]
Santa Casa da Misericórdia de Fortaleza
Fortaleza , 60025, Brazil More Info
Francisco Hidelbrando A Mota Filho
Contact
[email protected]
University of Patras
Patras , 265 0, Greece More Info
Evangelos Liatsikos
Contact
[email protected]
Urology, Andrology & Kidney Transplantation Unit, University of Bari
Bari , 70121, Italy More Info
Pasquale Ditonno
Contact
[email protected]
Policlinico S. Orsola Malpighi
Bologna , 40138, Italy More Info
Riccardo Schiavina
Contact
[email protected]
Department of Urology, University of Florence, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi Hospital
Firenze , 50100, Italy More Info
Andrea Mari
Contact
[email protected]
Policlinico Riuniti, Università di Foggia.
Foggia , 71122, Italy More Info
Giuseppe Carrieri
Contact
[email protected]
Gian Maria Busetto
Contact
[email protected]
Division of Urology, University of Genoa,Policlinico San Martino Hospital
Genova , 16132, Italy More Info
Carlo Terrone
Contact
[email protected]
Azienda Ospedaliera Policlinico "G. Martino", Università di Messina.
Messina , 98124, Italy More Info
Vincenzo Ficarra
Contact
[email protected]
San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital
Milano , 20132, Italy More Info
Umberto Capitanio
Contact
[email protected]
Policlinico Istituto Europeo di Oncologia (IEO)
Milano , 20141, Italy More Info
Ottavio De Cobelli
Contact
[email protected]
Istituto Nazionale dei Tumori Fondazione Senatore "G. Pascale"
Napoli , 80131, Italy More Info
Sisto Perdona'
Contact
[email protected]
Institute Oncology Veneto (IOV)
Padova , 35128, Italy More Info
Angelo Porreca
Contact
[email protected]
Humanitas Hospital
Rozzano , 20089, Italy More Info
Nicolomaria Buffi
Contact
[email protected]
Università degli Studi di Torino, Ospedale S. Luigi Gonzaga.
Torino , 10043, Italy More Info
Francesco Porpiglia
Contact
[email protected]
Università degli studi di Torino, Ospedale Molinette
Torino , 10126, Italy More Info
Paolo Gontero
Contact
[email protected]
AOUI Verona
Verona , 37126, Italy More Info
Alessandro Antonelli
Contact
[email protected]
Jikei University School of Medicine
Tokyo , 105-8, Japan More Info
Shin Egawa
Contact
[email protected]
Amsterdam University Medical Centers
Amsterdam , 1118, Netherlands More Info
Axel Bex
Contact
[email protected]
European Health Center
Otwock , 05-40, Poland More Info
Lukasz Nyk
Contact
[email protected]
Hubert Kamecki
Contact
[email protected]
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie
Warsaw , 00-00, Poland More Info
Roman Sosnowski
Contact
[email protected]
N.N. Blokhin National Medical Research Center of Oncology
Moscow , 11957, Russian Federation More Info
Vsevolod Matveev
Contact
[email protected]
NG Teng Fong General Hospital
Singapore , 60906, Singapore More Info
Vineet Gaauhaar
Contact
[email protected]
Fundaciò Puigvert
Barcelona , 08025, Spain More Info
Joan Palou
Contact
[email protected]
Hospital Universitario Ramón y Cajal, University of Alcalá
Madrid , 28034, Spain More Info
Vital Hevia
Contact
[email protected]
Bristol Urological Institute
Bristol , BS10 , United Kingdom More Info
Francis Keeley
Contact
[email protected]
Guy's Hospital
London , SE1 9, United Kingdom More Info
Ben Challacombe
Contact
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Estimated Enrollment:

10000

Study ID:

NCT05363657

Recruitment Status:

Recruiting

Sponsor:


Azienda Ospedaliero-Universitaria Careggi

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.